CN106880048A - 一种抗疲劳的保健食品 - Google Patents
一种抗疲劳的保健食品 Download PDFInfo
- Publication number
- CN106880048A CN106880048A CN201710301680.4A CN201710301680A CN106880048A CN 106880048 A CN106880048 A CN 106880048A CN 201710301680 A CN201710301680 A CN 201710301680A CN 106880048 A CN106880048 A CN 106880048A
- Authority
- CN
- China
- Prior art keywords
- health food
- powder
- antifatigue
- maca
- food according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013402 health food Nutrition 0.000 title claims abstract description 35
- 230000002929 anti-fatigue Effects 0.000 title claims abstract description 29
- 239000000843 powder Substances 0.000 claims abstract description 41
- 235000000421 Lepidium meyenii Nutrition 0.000 claims abstract description 37
- 240000000759 Lepidium meyenii Species 0.000 claims abstract description 37
- 235000012902 lepidium meyenii Nutrition 0.000 claims abstract description 37
- 241000383638 Allium nigrum Species 0.000 claims abstract description 22
- 244000269722 Thea sinensis Species 0.000 claims abstract description 21
- 235000009569 green tea Nutrition 0.000 claims abstract description 21
- 229940029982 garlic powder Drugs 0.000 claims abstract description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 10
- 235000009508 confectionery Nutrition 0.000 claims description 9
- 235000013361 beverage Nutrition 0.000 claims description 5
- 235000021552 granulated sugar Nutrition 0.000 claims description 5
- 239000004310 lactic acid Substances 0.000 claims description 5
- 235000014655 lactic acid Nutrition 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 230000000996 additive effect Effects 0.000 claims description 4
- 235000003599 food sweetener Nutrition 0.000 claims description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 4
- 239000003765 sweetening agent Substances 0.000 claims description 4
- 239000000811 xylitol Substances 0.000 claims description 4
- 235000010447 xylitol Nutrition 0.000 claims description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 4
- 229960002675 xylitol Drugs 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 238000004040 coloring Methods 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 235000019634 flavors Nutrition 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 230000002335 preservative effect Effects 0.000 claims description 3
- 230000000844 anti-bacterial effect Effects 0.000 claims description 2
- 239000003899 bactericide agent Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 235000015203 fruit juice Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 235000013599 spices Nutrition 0.000 claims description 2
- 235000000346 sugar Nutrition 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- 230000036541 health Effects 0.000 abstract description 3
- 230000007774 longterm Effects 0.000 abstract description 3
- 230000000118 anti-neoplastic effect Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 206010016256 fatigue Diseases 0.000 description 26
- 206010028980 Neoplasm Diseases 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000032683 aging Effects 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 230000009182 swimming Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 description 4
- 235000013824 polyphenols Nutrition 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- YVWMHFYOIJMUMN-CYZWUHAYSA-N (6e,8e)-5-oxooctadeca-6,8-dienoic acid Chemical compound CCCCCCCCC\C=C\C=C\C(=O)CCCC(O)=O YVWMHFYOIJMUMN-CYZWUHAYSA-N 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 235000005979 Citrus limon Nutrition 0.000 description 3
- 244000131522 Citrus pyriformis Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000001630 malic acid Substances 0.000 description 3
- 235000011090 malic acid Nutrition 0.000 description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000004376 Sucralose Substances 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000011122 softwood Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 235000019408 sucralose Nutrition 0.000 description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000001040 synthetic pigment Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 235000020985 whole grains Nutrition 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 240000001592 Amaranthus caudatus Species 0.000 description 1
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- VYBYUSNZEMCCFQ-UHFFFAOYSA-N C=CC=CCC.[K] Chemical compound C=CC=CCC.[K] VYBYUSNZEMCCFQ-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010057315 Daydreaming Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-N E-Sorbic acid Chemical compound C\C=C\C=C\C(O)=O WSWCOQWTEOXDQX-MQQKCMAXSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- PVKQULHHWVQXLE-UHFFFAOYSA-N Glycyrol Natural products C12=CC=C(O)C=C2OC2=C1C(=O)OC1=C2C(O)=C(CC=C(C)C)C(OC)=C1 PVKQULHHWVQXLE-UHFFFAOYSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 239000004384 Neotame Substances 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241001165494 Rhodiola Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- ZIALXKMBHWELGF-UHFFFAOYSA-N [Na].[Cu] Chemical compound [Na].[Cu] ZIALXKMBHWELGF-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000004178 amaranth Substances 0.000 description 1
- 235000012735 amaranth Nutrition 0.000 description 1
- 210000003056 antler Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- LWESBHWAOZORCQ-UHFFFAOYSA-N glycyrol Chemical compound C12=CC=C(O)C=C2OC2=C1C(=O)OC1=C2C(OC)=C(CC=C(C)C)C(O)=C1 LWESBHWAOZORCQ-UHFFFAOYSA-N 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 239000004223 monosodium glutamate Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 1
- 229930019673 naringin Natural products 0.000 description 1
- 229940052490 naringin Drugs 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 235000019412 neotame Nutrition 0.000 description 1
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 description 1
- 108010070257 neotame Proteins 0.000 description 1
- -1 nipagin esters Chemical class 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 235000015206 pear juice Nutrition 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 1
- 239000004324 sodium propionate Substances 0.000 description 1
- 235000010334 sodium propionate Nutrition 0.000 description 1
- 229960003212 sodium propionate Drugs 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及保健品领域，具体而言，涉及一种抗疲劳的保健食品。按重量份计，所述保健食品包括：玛咖根粉0.5～7份、玛咖提取物0.05～2份、黑蒜粉0.05～2份以及绿茶粉0.005～0.05份。所述保健食品具有显著的抗疲劳、抗肿瘤的效果，适合各年龄段人群长期服用，对人体无明显的毒副作用，可大幅度改善疲劳人群生活质量。
Description
技术领域
本发明涉及保健品领域，具体而言，涉及一种抗疲劳的保健食品。
背景技术
疲劳是指机体生理过程不能持续其机能的特定水平上或不能维持预定的运动强度。关于疲劳发生的机理，Edward曾提出“突变理论”，其认为整体性疲劳不是固定由某一种或几种原因引起的，它是多种致疲劳因素总和的产物，运动疲劳前肌肉的兴奋性、能量供应水平、输出功率呈一个逐渐下降的过程。当各种致疲劳因素的总和效应达到一定的临界值时，就会出现一个突然的下降，表现为兴奋性突然崩溃、能量供应突然阻断、肌肉力量或输出功率陡然下降，于是出现了疲劳。
疲劳是一个涉及许多生理生化因素的综合性的生理过程，引起疲劳的原因有很多，包括工作环境、饮食习惯和生活习性等方面，特别是疾病，导致患者的精神紧张、体力消耗、身体各个机能的抵抗力减弱以及药物对体力的消耗，极易产生疲劳感。疲劳是机体脑力活动或体力活动到一定阶段时必然出现的一种正常的生理现象，既标志着机体原有工作能力的暂时下降，又有可能是机体发展到伤病状态的一个先兆。20世纪80年代以后，知识在爆炸，生活节奏不断加快，充斥人生各阶段的竞争也日益激烈。但是，人类的生理功能并没有因此而有相应的进化。如此超负荷的运转，给人类健康带来了极大的危害。据专家统计，全球人口约35％以上处于疲劳状态。
疲劳的危害颇多，其使得机体各系统的功能处在一个较低的水平，机体抵抗外来病原物的能力降低，自然杀伤细胞的减少，人就极易生病。同时人体自然杀伤细胞的减少会使心脑血管疾病、糖尿病、癌症等高危病症的发生概率大大增加。当人体处在疲劳状态时，由于心肌细胞能量的减少和生理疲劳对心肌细胞的毒害，心肌收缩力变小，心脏的泵血功能降低，血液淤积在血管之中，发生微循环障碍，血流速度减慢，血液垃圾增多，引发各种心脑血管疾病。此外，过度的疲劳就会使机体的衰老产生“衰老加速度”。在人中年以后，正常的机体衰老速度是每年1％～5％，一旦患有生理疲劳，机体的衰老速度会不断增加，衰老加速的直接后果就是原本需要50年的衰老过程可能15年就完成了。
目前，肿瘤是经济发达国家中导致人们死亡的首要原因，是发展中国家中导致人们死亡的第二原因。疲劳是肿瘤患者经历的最常见的不适症状之一。美国国立综合癌症网络公布的肿瘤相关性疲劳(Cancer related Fatigue，CRF)临床实践指南(2012.1版)将CRF定义为，是一种与肿瘤或肿瘤治疗相关、与近期活动不成比例且影响日常生活的一种令人持续不适的，躯体、情感和/或认知方面的主观疲惫或疲倦感。CRF可以是由肿瘤本身引起，也可是肿瘤的诊疗过程(如接受化疗、放疗、骨髓移植，或应用生物反应调节剂等)中出现的，也是肿瘤患者的一个重要并且独立的生活的质量和满意度的预测因子。CRF仍然持续被低估，并且常常没有得到治疗。
此外，疲劳症状中的慢性疲劳综合征(Chronic Fatigue Syndrome，简称CFS)也日益受到了人们的关注，CFS是一组以长期持续疲劳为突出表现，同时伴有低热、头痛、咽喉痛、肌肉关节痛、注意力不集中、记忆力下降、睡眠障碍和抑郁等非特异性表现为主的一组征候群，体格检查和常规检查一般无明显异常。CFS好发于20～50岁年龄组，以女性多见。CFS对患者的工作和生活造成较严重的影响，日益受到医学界的高度关注。
缓解疲劳的方法大多通过睡眠、休养进行机体调整，另一方面依靠外在物质的调理提高身体机能。但纵观目前的市场，尚没有一款效果非常显著的用于抗疲劳的药物或食品。中国专利申请CN 105125954A公开了黑蒜及玛卡具有提高生育能力和增强体力的效果，但其抗疲劳的能力较弱，不能很好地满足人们的需求。
有鉴于此，特提出本发明。
发明内容
本发明的目的在于提供一种抗疲劳的保健食品，所述保健食品具有显著的抗疲劳能力，兼具抗肿瘤效果，无明显的毒副反应。
本发明的抗疲劳的保健食品，按重量份计，包括如下组份：
玛咖根粉0.5～7份、玛咖提取物0.05～2份、黑蒜粉0.05～2份以及绿茶粉0.005～0.05份。
与现有技术相比，本发明的有益效果为：
(1)符合中医配伍原则，各味主要原料的搭配起到了显著的增效作用。
(2)营养丰富，吸收快，能够快速调节人体机能。
(3)具有显著的抗疲劳抗肿瘤的效果，适合各年龄段人群长期服用，对人体无明显的毒副作用，可大幅度改善疲劳人群生活质量。
具体实施方式
本发明一方面涉及一种抗疲劳的保健食品，主要由以下原料制成：玛咖根粉、玛咖提取物、黑蒜粉以及绿茶粉。
其中，各原料可为具有既定范围的有效成分的市售产品；
优选的，所述玛咖提取物中含有介子油苷≥0.1％，玛咖酰胺与玛咖烯之和≥0.1％；更优选的含有介子油苷0.5％～10％，玛咖酰胺与玛咖烯之和0.3％～3％；或介子油苷1％～5％，玛咖酰胺与玛咖烯之和0.6％～1.2％。
优选的，所述绿茶粉中茶多酚含量≥50％，也可以为50％～99％，50％～80％或50％～60％。
以上均为质量百分数。
按重量份数计，包括如下组份：
玛咖根粉0.5～7份、玛咖提取物0.05～2份、黑蒜粉0.05～2份以及绿茶粉0.005～0.05份。
优选的，如上所述的抗疲劳的保健食品，按重量份计，所述保健食品包括：
玛咖根粉1～5份、玛咖提取物0.1～1份、黑蒜粉0.1～1份以及绿茶粉0.005～0.02份。
优选的，如上所述的抗疲劳的保健食品，按重量份计，所述保健食品包括：
玛咖根粉2～4份、玛咖提取物0.3～0.8份、黑蒜粉0.3～0.8份以及绿茶粉0.005～0.015份。
优选的，如上所述的抗疲劳的保健食品，按重量份计，所述保健食品包括：
玛咖根粉3份、玛咖提取物0.5份、黑蒜粉0.5份以及绿茶粉0.01份。
中医认为，疲劳现象的出现，与五脏的失调有密切的关系，如四肢无力多与脾胃有关，腰酸腿软多与肾脏有关，气力不足多与肺脏有关，头脑不清多与心脏有关，不耐疲劳多与肝脏有关。
君药玛咖根粉、玛咖提取物：性温，甘、平。归肺、肾经。补肾益肺、增强肌肉运动能力。
臣药黑蒜：甘，温。归肝经。益胃、精神，强化内脏功能。
佐药绿茶(茶多酚含量≥50％)：性微寒，甘、苦。归心、肺、胃经。抗疲劳，茶多酚抗氧化能力是VE的20倍。
添加绿茶粉(茶多酚含量≥50％)后组方归经五脏具全，肝心脾肺肾对应着木火土金水，五行相生相克，和谐统一，抗疲劳效果显著增强。
在一种实施方式中，本发明所提供的保健食品为颗粒剂、胶囊、压片糖果或速溶固体饮料。
优选的，如上所述的抗疲劳的保健食品，所述保健食品还包括粘稠剂、甜味剂、调味剂、着色剂、营养添加剂、防腐剂、杀菌剂、香料中的一种或多种。
更优选的，所述粘稠剂包括澄粉、蛋白、卡德兰胶、羧甲基纤维素(CMC)、海藻酸钠、鹿角菜胶、羧甲基纤维素钠；最优选为糊精或淀粉。
更优选的，所述甜味剂包括白砂糖、葡萄糖、寡糖、果糖、麦芽糖、阿斯巴甜、糖精、蔗糖素、醋磺内脂钾、三氯蔗糖、纽甜、甘草醇、安赛蜜、甜菊苷、甘草素、山梨糖醇、麦芽糖醇、木糖醇中的一种或多种；最优选包括白砂糖、葡萄糖、红糖或木糖醇中的一种或多种。
更优选的，所述调味剂包括柠檬酸、苹果酸、乳酸、乙酸、咖啡碱、柚苷、味精、L-麸胺酸钠中的一种或多种，最优选包括柠檬酸、苹果酸或乳酸中的一种或多种；最优选包括柠檬酸、苹果酸或乳酸中的一种或多种。
更优选的，所述着色剂为食品合成色素和/或食品天然色素。
更优选的，所述食品合成色素选自以下色素的一种或多种：苋菜红、胭脂红、赤藓红、新红、诱惑红、柠檬黄、日落黄、亮蓝、靛蓝以及它们各自的铝色淀，以及酸性红、β-胡萝卜素、叶绿素铜钠和二氧化钛。
更优选的，所述营养添加剂包括乳制品、蛋制品或果汁中的一种或多种，还可以添加一些维生素或氨基酸类物质等。
更优选的，所述防腐剂包括亚硝酸钠、亚硝酸、己二烯酸钾、己二烯酸、丙酸钠、对羟基苯甲酸酯(尼泊金酯)中的一种或多种。
下面将结合实施例对本发明的实施方案进行详细描述，但是本领域技术人员将会理解，下列实施例仅用于说明本发明，而不应视为限制本发明的范围。实施例中未注明具体条件者，按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者，均为可以通过市购买获得的常规产品。
实施例1
称量玛咖根粉1kg、玛咖提取物2kg、黑蒜粉2kg以及绿茶粉0.005kg混合均匀，以羟甲基丙基纤维素的水溶液为粘合剂制软材，过20目筛制粒，65℃条件进行干燥，再过18目筛整粒，混入I份硬脂酸镁，压片，得到玛咖黑蒜绿茶压片糖果。
实施例2
称量玛咖根粉5kg、玛咖提取物0.1kg、黑蒜粉1kg以及绿茶粉0.01kg混合均匀制成软材，向其中再加入木糖醇0.05kg、柠檬酸0.01kg、糊精1kg、浓缩梨汁20ml混匀，65℃条件进行干燥，再过20目筛整粒，混入I份硬脂酸镁，压片，得到玛咖黑蒜绿茶压片糖果。
实施例3
称量玛咖根粉2kg、玛咖提取物0.3kg、黑蒜粉0.8kg、绿茶粉0.015kg、诱惑红0.005kg并混匀，常规方法灭菌，用微波在60℃下干燥；之后粉碎成过100目筛干粉，将所得干粉与白砂糖0.3kg混匀，再次60℃微波干燥，造粒装袋包装既得固体饮料，
实施例4
称量玛咖根粉3kg、玛咖提取物0.5kg、黑蒜粉0.5kg、绿茶粉0.01kg并混匀，常规方法灭菌，用微波在60℃下干燥；之后粉碎成过100目筛的干粉，将所得干粉与白砂糖0.3kg混匀，再次60℃微波干燥，造粒装袋包装既得固体饮料，
实验例1
动物分组：对小鼠进行称量之后，将100只小鼠分成两大组，每大组小鼠50只，两批小鼠分别进行游泳力竭实验和生化指标测试。每批小鼠再随机分为5组，空白对照组10只，样品组高中低各10只，阳性组(红景天)10只，对比例组10只。空白对照组不灌胃。每组灌胃7天。
对比例组采用公开号为CN105125954 A，公开日为2015年12月9日的专利文件中第四实施例中的配方，灌胃剂量做出调整。
样品组由玛咖根粉3重量份、玛咖提取物0.5重量份、黑蒜粉0.5重量份、绿茶粉0.01重量份的比例加水稀释后制得。
表1各组小鼠负重游泳力竭时间的测定结果
注：与空白对照组比较，*P＜0.05，**P＜0.01。
负重力游泳实验：末次灌胃30min后，在小鼠尾根部负重5％体重的铅皮，置于30℃的游泳箱内，记录小鼠开始游泳至头部全部入水超过八秒不能浮出水面的时间为其力竭游泳时间。
表2各组小鼠血清尿素氮和乳酸脱氧酶含量(n＝10)
注：与空白对照组比较，*P＜0.05，**P＜0.01。
与空白对照组比较，中、高剂量组肝糖原、肌糖原含量升高明显，中剂量组有显著性差异(P<0.05)，高剂量组有极显著性差异(P<0.01)。说明目标样品具有明显的抗疲劳作用。
实验例2
挑选生长状态良好的细胞经0.25％胰蛋白酶消化，终止消化后洗涤2次，再用含10％胎牛血清DMEM培养液配制成单个细胞悬液，以每孔1×104个细胞接种于96孔培养板内，每孔100μl。培养24h后，吸弃培养液，将玛卡黑蒜压片糖果按实验设计(表1)所需的浓度分别加入各孔，每孔200μL，每组设3个复孔，分别设：调零组(培养液)、空白组(培养液)、对比例组(CN105125954A第四实施例，终浓度为10mg/mL)实验组(实施例4的固体饮料做系列稀释)及阳性对照组(5–氟尿嘧啶终浓度为20μg/mL)。于CO2培养箱中37℃培养44h后，每孔加入5mg/mL MTT20μL，37℃继续孵育4h，取出96孔板，吸弃培养液，每孔加入150μL DMSO，震荡l0min使结晶物充分溶解，取至微型离心管中稀释至1000μL，紫外分光光度计于波长570nm下检测每孔的吸收度(OD值)。每次实验重复三次，试验结果如下表：
表3肿瘤细胞抑制试验结果
结论：玛卡黑蒜压片糖果能够抑制肿瘤细胞细胞生长导致肿瘤细胞死亡，该样品具有良好的抗肿瘤效果。
尽管已用具体实施例来说明和描述了本发明，然而应意识到，在不背离本发明的精神和范围的情况下可以作出许多其它的更改和修改。因此，这意味着在所附权利要求中包括属于本发明范围内的所有这些变化和修改。
Claims (10)
1.一种抗疲劳的保健食品，其特征在于，按重量份计，所述保健食品包括：
玛咖根粉0.5～7份、玛咖提取物0.05～2份、黑蒜粉0.05～2份以及绿茶粉0.005～0.05份。
2.根据权利要求1所述的抗疲劳的保健食品，其特征在于，按重量份计，所述保健食品包括：
玛咖根粉1～5份、玛咖提取物0.1～1份、黑蒜粉0.1～1份以及绿茶粉0.005～0.02份。
3.根据权利要求1所述的抗疲劳的保健食品，其特征在于，按重量份计，所述保健食品包括：
玛咖根粉2～4份、玛咖提取物0.3～0.8份、黑蒜粉0.3～0.8份以及绿茶粉0.005～0.015份。
4.根据权利要求1所述的抗疲劳的保健食品，其特征在于，按重量份计，所述保健食品包括：
玛咖根粉3份、玛咖提取物0.5份、黑蒜粉0.5份以及绿茶粉0.01份。
5.根据权利要求1～4任一项所述的抗疲劳的保健食品，其特征在于，所述保健食品为颗粒剂、胶囊、压片糖果或速溶固体饮料。
6.根据权利要求1～4任一项所述的抗疲劳的保健食品，其特征在于，所述保健食品还包括粘稠剂、甜味剂、调味剂、着色剂、营养添加剂、防腐剂、杀菌剂、香料中的一种或多种。
7.根据权利要求6所述的抗疲劳的保健食品，其特征在于，所述粘稠剂包括糊精或淀粉。
8.根据权利要求6所述的抗疲劳的保健食品，其特征在于，所述甜味剂包括白砂糖、葡萄糖、红糖或木糖醇中的一种或多种。
9.根据权利要求6所述的抗疲劳的保健食品，其特征在于，所述调味剂包括柠檬酸、苹果酸或乳酸中的一种或多种。
10.根据权利要求6所述的抗疲劳的保健食品，其特征在于，所述营养添加剂包括乳制品、蛋制品或果汁中的一种或多种。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710301680.4A CN106880048A (zh) | 2017-05-02 | 2017-05-02 | 一种抗疲劳的保健食品 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710301680.4A CN106880048A (zh) | 2017-05-02 | 2017-05-02 | 一种抗疲劳的保健食品 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106880048A true CN106880048A (zh) | 2017-06-23 |
Family
ID=59183099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710301680.4A Pending CN106880048A (zh) | 2017-05-02 | 2017-05-02 | 一种抗疲劳的保健食品 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106880048A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT202100011609A1 (it) | 2021-05-06 | 2022-11-06 | Perfetti Van Melle Spa | Prodotto di confetteria |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103652092A (zh) * | 2013-11-26 | 2014-03-26 | 杭州艺福堂茶业有限公司 | 一种玛咖茶口服片及其制备方法 |
| CN103766907A (zh) * | 2014-02-20 | 2014-05-07 | 云南众爱生物科技有限公司 | 一种纯玛咖片及其制备方法 |
| CN103976435A (zh) * | 2014-04-18 | 2014-08-13 | 赵之光 | 一种玛咖功能型饮料及其制备方法 |
| KR20140103572A (ko) * | 2013-02-18 | 2014-08-27 | (주)엠피위즈 | 아르기닌, 마카추출분말, 구연산 및 폴리덱스트로스를 주성분으로 함유하는 기능성 액상 조성물 |
| CN105433391A (zh) * | 2015-12-22 | 2016-03-30 | 天津喜马拉雅健康科技有限公司 | 一种纯玛咖片及其制备方法 |
| CN105639650A (zh) * | 2016-01-14 | 2016-06-08 | 昆明康嘉乐生物科技有限公司 | 一种高效玛咖精片及其制备方法 |
| CN106344774A (zh) * | 2016-09-25 | 2017-01-25 | 安徽旺润生物科技有限公司 | 一种黑蒜玛咖片 |
-
2017
- 2017-05-02 CN CN201710301680.4A patent/CN106880048A/zh active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140103572A (ko) * | 2013-02-18 | 2014-08-27 | (주)엠피위즈 | 아르기닌, 마카추출분말, 구연산 및 폴리덱스트로스를 주성분으로 함유하는 기능성 액상 조성물 |
| CN103652092A (zh) * | 2013-11-26 | 2014-03-26 | 杭州艺福堂茶业有限公司 | 一种玛咖茶口服片及其制备方法 |
| CN103766907A (zh) * | 2014-02-20 | 2014-05-07 | 云南众爱生物科技有限公司 | 一种纯玛咖片及其制备方法 |
| CN103976435A (zh) * | 2014-04-18 | 2014-08-13 | 赵之光 | 一种玛咖功能型饮料及其制备方法 |
| CN105433391A (zh) * | 2015-12-22 | 2016-03-30 | 天津喜马拉雅健康科技有限公司 | 一种纯玛咖片及其制备方法 |
| CN105639650A (zh) * | 2016-01-14 | 2016-06-08 | 昆明康嘉乐生物科技有限公司 | 一种高效玛咖精片及其制备方法 |
| CN106344774A (zh) * | 2016-09-25 | 2017-01-25 | 安徽旺润生物科技有限公司 | 一种黑蒜玛咖片 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT202100011609A1 (it) | 2021-05-06 | 2022-11-06 | Perfetti Van Melle Spa | Prodotto di confetteria |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107897905A (zh) | 一种降糖营养粉及其制备方法和应用 | |
| US10149882B2 (en) | Weight management systems and related methods | |
| KR102299934B1 (ko) | 숙취해소에 뛰어나며 알코올에 의한 간 손상을 예방 또는 치료용 조성물 | |
| US10485836B2 (en) | Anti-fatigue composition used for increasing endurance performance, and use of the same | |
| CN103493865B (zh) | 一种适合高血压人群食用的饼干及其制备方法 | |
| CN107996975A (zh) | 一种含牛蒡多糖的藜麦减肥代餐粉 | |
| CN107455625A (zh) | 一种具有抗疲劳减肥功能的植物营养素饮料及其制备工艺 | |
| CN102113652A (zh) | 一种适合“五高”代谢综合症人群的特膳挤压米及其制备方法 | |
| CN105394546A (zh) | 一种黑苦荞精华含片及其加工方法 | |
| CN107319242A (zh) | 左旋肉碱减肥泡腾片及其制备方法 | |
| CN107048329A (zh) | 一种富锌保健盐及其制备方法 | |
| CN106880048A (zh) | 一种抗疲劳的保健食品 | |
| CN102090637A (zh) | 一种含有胶原蛋白的复方营养粉 | |
| JP2006197911A (ja) | 蜂の子利用の健康食品。 | |
| CN107348350A (zh) | 一种调节血糖的面条及其制备方法 | |
| CN103621871B (zh) | 一种复合氨基酸保健品及其制备方法 | |
| Mahata | Importance of buckwheat (Fagopyrum esculentum Moench) | |
| CN107440113A (zh) | 纸上活体综合胚芽功能性微量激活源及其制备方法 | |
| CN104687118A (zh) | 营养型减肥速溶粉 | |
| CN107549614A (zh) | 一种食疗调理三高的膳食粉及其制备方法 | |
| RU2464986C1 (ru) | Способ проф. игнатьева снижения массы тела человека | |
| RU2781249C1 (ru) | Специализированный пищевой продукт для диетического лечебного и диетического профилактического питания детей старше трех лет и способ его применения | |
| CN107242570A (zh) | 一种提高免疫力抗疲劳的保健食品 | |
| US10471007B2 (en) | Sublingual therapeutic solutions and methods | |
| CN108185418A (zh) | 一种复合营养食疗剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170623 |